SUNNYVALE, Calif.--(BUSINESS WIRE)--Global ophthalmic company OptiMedica Corp. has announced it has nearly tripled its operation size with the move to a new 55,000 square foot facility located at 1310 Moffett Park Drive, Sunnyvale, Calif. 94089. The expanded global headquarters, which houses all business functions, is the new base of the company’s worldwide commercial launch of the Catalys™ Precision Laser System for cataract surgery.
“The move to our expanded headquarters marks the beginning of an exciting new growth phase for OptiMedica,” said Mark J. Forchette, OptiMedica president and chief executive officer. “Worldwide surgeon interest in Catalys is significant and increasing every day, and our new, larger facility will enable us to rapidly scale our operations, appropriately serve customer needs and meet the growing global demand.”
OptiMedica’s Catalys Precision Laser System is U.S. Food and Drug Administration 510(k) market cleared and CE mark approved for performing capsulotomy and lens fragmentation during cataract surgery. The system is now available at leading ophthalmic centers in the United States and around the world.
About the Catalys Precision Laser System
Catalys combines a femtosecond laser, integrated 3D Optical Coherence Tomography (OCT) imaging and OptiMedica’s breakthrough pattern scanning technology in an ergonomic, easy-to-use system that delivers a precise, customized procedure for patients. Distinguishing features include a Liquid Optics™ Interface that ensures stable system-patient attachment and optimizes the optical path to the patient’s eye, and a proprietary Integral Guidance™ system that ensures the femtosecond laser pulses are delivered safely and precisely to the intended location. In addition, Catalys features an easy-to-use and elegant graphical user interface designed to simplify the planning process, minimize treatment time and maximize throughput.
Founded in 2004 and headquartered in Sunnyvale, Calif., OptiMedica Corp. is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. Exclusively focused in the cataract therapeutic area, the company has developed the Catalys Precision Laser System to deliver unequaled precision and accuracy and a markedly streamlined workflow to the laser cataract procedure.
OptiMedica’s legacy of innovation in ophthalmology also includes the development and commercialization of the PASCAL® Method of retinal photocoagulation, which was acquired by Topcon Corp. in August 2010. The company is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital. For more information, please visit www.optimedica.com.